Open Innovation

About  DNDi Open Innovation

Pharmaceutical companies have vast, well-curated libraries of novel, proprietary drug-like compounds built up over decades of research into various disease areas. They also have access to state-of-the-art (and often proprietary) algorithms and computational approaches for assessing chemical ‘similarity’ between molecules. These resources are usually closely guarded and not shared externally – certainly not between competitors.

To speed up early-stage research and reduce overall R&D costs, DNDi works to enable research actors to actively collaborate without the restraints of intellectual property, supporting and coordinating a number of open innovation collaborations , including the NTD Drug Development Booster, Mycetoma Open Source project (MycetOS), and Open Synthesis Network (OSN).

DNDi’s Open Innovation Portal: dndi.org/openinnovation